Saturday, 31 October 2026European Markets

FDJ And ELOPAK Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - fdj (fdj.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
fdj (fdj.pa) €37.78 4.81% 42.59%
elopak (elo.ol) kr33.70 3.83% 22.46%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. fdj (fdj.pa)

4.81% forward dividend yield and 42.59% return on equity

la française des jeux société anonyme engages in the gaming operation and distribution business in france and internationally. it offers lottery games, such as draw and instant games at points of sale and online; sports betting at points of sale; online poker; online horse-race and sports betting; betting and risk management services to sports betting operators; digital gaming platform; and s sports betting technology, as well as holds and administers draws for participating lotteries. the company was founded in 1933 and is headquartered in boulogne-billancourt, france.

earnings per share

as for profitability, fdj has a trailing twelve months eps of €2.23.

pe ratio

fdj has a trailing twelve months price to earnings ratio of 16.94. meaning, the purchaser of the share is investing €16.94 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 42.59%.

volume

today's last reported volume for fdj is 149175 which is 19.76% below its average volume of 185922.

more news about fdj.

2. elopak (elo.ol)

3.83% forward dividend yield and 22.46% return on equity

elopak asa manufactures and supplies paper-based packaging solutions for liquid food in europe, the middle east, africa, asia, the americas, and internationally. it offers pure-pak cartons for chilled and aseptic liquid food; common roll fed aseptic carton; d-pak cartons for non food products for personal and home care; and filling equipment. it also offers standard flexo, super flexo, uv-flexo, and offset litho printing services, as well as digital print proofs and machine print proofs on paper board. further, it provides machines and equipment through spare part webshop. elopak asa was founded in 1957 and is headquartered in oslo, norway.

earnings per share

as for profitability, elopak has a trailing twelve months eps of kr2.79.

pe ratio

elopak has a trailing twelve months price to earnings ratio of 12.08. meaning, the purchaser of the share is investing kr12.08 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.46%.

more news about elopak.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com